
MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.

MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.

Disability in MS accrues through two distinct biological engines. Recognizing relapse-independent progression changes how clinicians assess patients and how they build trust with those who feel worse despite stable MRI.

Relapsing and progressive biology coexist in every patient, and clinical tools remain blunt. The panel considers biomarkers, treatable comorbidities, and rehabilitation before attributing worsening to MS progression.

Treating MS as a continuum conflicts with phenotype-based coding and payer criteria. The panel describes how those frameworks restrict access for patients who are progressing without recent relapses.

Early high-efficacy treatment is now common, but the field has not settled how long patients should stay on B-cell depletion. Two randomized strategy trials may clarify who needs which approach.

Serum biomarkers, baseline immunoglobulin testing, and patient preference are reshaping individualized MS care. The panel also imagines a Framingham-style risk score to guide how aggressively to treat.